Endoprosthesis having a stable architecture

Information

  • Patent Grant
  • 8920488
  • Patent Number
    8,920,488
  • Date Filed
    Thursday, December 20, 2007
    17 years ago
  • Date Issued
    Tuesday, December 30, 2014
    10 years ago
Abstract
The present invention relates to an endoprosthesis having a web structure that is expandable from a contracted configuration to an expanded configuration and that includes a plurality of longitudinally adjacent web rings. Each of the web rings is defined by web elements disposed circumferentially around a longitudinal axis, which are adjoined one to the other at junction bends. A first junction bend in a first web ring is coupled to a second junction bend in a second web ring by a connector which includes three or more struts of essentially equal length that extend circumferentially in essentially parallel directions. The struts of the connector are adjoined in sequence by coupling segments that, in one embodiment of the invention, are arcuate in shape.
Description
FIELD OF THE INVENTION

The present invention relates to an endoprosthesis having elevated scaffolding properties and also elevated flexibility. More particularly, the present invention relates to an endoprosthesis having a plurality of web rings coupled by connectors that are composed of three or more struts of essentially equal length, which extend circumferentially in essentially parallel directions.


BACKGROUND OF THE INVENTION

Applications of endoprotheses to the superior femoral artery (SFA) and to the popliteal artery (PA) has received increased attention because of the prevalence of peripheral arterial disease (PAD) among older patients and because no known endoprosthesis can adequately supports the SFA and the PA without distorting its architecture during patient motion.


PAD is estimated to affect between 3% and 10% of individuals till the age of 70 and may approach 20% of individuals older than 70 years of age. PAD has been associated with an increased risk of coronary artery disease, cerebrovascular disease, and premature death. Moreover, as a consequence of limited exercise performance and walking ability, individuals who have symptoms of intermittent claudication experience a significantly negative impact on quality of life.


Exercise programs have been recommended as the first line of therapy for PAD. Pharmacotherapy with cilostazol provides additional symptom relief, but patients who fail medical therapy and continue to have resting leg pain or non-healing ulcers eventually become candidates for invasive treatment strategy. Unfortunately, surgical revascularization has associated with higher periprocedural morbidity and mortality, making the surgical option less desirable in elderly patients—a significant proportion of patients with PAD.


Because greater than 50% of individuals with lower extremity claudication have atherosclerotic disease confined to the superficial femoral artery (SFA), endovascular techniques have recently emerged to treat this arterial segment.


Stents, grafts and a variety of other endoprostheses are well known and used in endovascular procedures, such as for treating aneurysms, lining or repairing vessel walls, filtering or controlling fluid flow, and expanding or scaffolding occluded or collapsed vessels. Such endoprostheses can be delivered and used in virtually any accessible body lumen of a human or animal and can be deployed by any of a variety of recognized means.


An endoprosthesis is typically delivered by a catheter system to a desired location or deployment site inside a body lumen of a vessel or other tubular organ. To facilitate such delivery, the endoprosthesis must be capable of having a particularly small cross profile and a sufficient degree of longitudinal flexibility during delivery to allow advancement through the anatomy to the deployed site.


Once deployed, the endoprosthesis should be capable of satisfying a variety of performance characteristics. The endoprosthesis should have sufficient rigidity or outer bias to perform its intended function, such as opening a lumen or supporting a vessel wall. Similarly, the endoprosthesis should retain sufficient flexibility along its length in its expanded condition so that it will not kink, straighten or fracture during or after deployment in a curved vessel. The endoprosthesis should also provide a substantially uniform or otherwise controlled scaffolding of the vessel wall and prevent plaque from protruding into the artery.


One type of endoprosthesis is the stent, which is used for the treatment of atherosclerotic stenosis in blood vessels. After a patient undergoes a percutaneous transluminal angioplasty or similar interventional procedure, a stent may be deployed at the treatment site to maintain patency of the vessel. The stent is configured to scaffold or support the treated blood vessel and may be loaded with a beneficial agent, acting as a delivery platform to reduce restenosis or the like.


Numerous endoprosthesis designs and constructions have been developed to address one or more of the performance characteristics summarized above. For example, a variety of stent designs are disclosed in the following patents: U.S. Pat. No. 4,580,568 to Gianturco; U.S. Pat. No. 5,102,417 to Palmaz; U.S. Pat. No. 5,104,404 to Wolff; U.S. Pat. No. 5,133,732 to Wiktor; U.S. Pat. No. 5,292,331 to Boneau; U.S. Pat. No. 5,514,154 to Lau et al.; U.S. Pat. No. 5,569,295 to Lam; U.S. Pat. No. 5,707,386 to Schnepp-Pesch et al.; U.S. Pat. No. 5,733,303 to Israel et al.; U.S. Pat. No. 5,755,771 to Penn et al.; U.S. Pat. No. 5,776,161 to Globerman; U.S. Pat. No. 5,895,406 to Gray et al.; U.S. Pat. No. 6,033,434 to Borghi; U.S. Pat. No. 6,099,561 to Alt; U.S. Pat. No. 6,106,548 to Roubin et al.; U.S. Pat. No. 6,113,627 to Jang; U.S. Pat. No. 6,132,460 to Thompson; U.S. Pat. No. 6,331,189 to Wolinsky; and U.S. Pat. No. 7,128,756 to Lowe et al., the entireties of which are incorporated herein by reference.


During the treatment of some types of SFA and PA disease, relatively long stent lengths are frequently required, at times causing the treating physician to overlap multiple stents. Further complicating the treatment of SFA and PA disease is the possibility of stent fractures and subsequent restenosis. A particular area of vulnerability is the area through the adductor canal as the SFA continues behind the knee; in fact, the area at the adductor canal is a frequent location for SFA disease likely secondary to the bending, compression, elongation and torsion forces on the artery itself due to the muscular structure surrounding this canal, leading to a lengthening and shortening of up to 15% of the stent between straight and bent positions of a limb. After the stent has been implanted, the body vessel is subjected to repeated traumas caused by the negative interaction of a relatively rigid stent and a softer artery.


In the earlier days of endovascular therapy, it was believed that the area to avoid stenting due to the risk of stent crush or stent fracture was near the bony articulation between the femur and the tibia. It is now believed that the area of critical importance is really superior to this point leading up to the adductor canal, which is a frequent location of SFA lesions. If it is necessary to stent this region, the ability of the stent to withstand the forces present in the SFA is of critical importance. Another risk is the incidence of restenosis, against which self-expanding Nitinol stents have shown better one-year patency rates than other types of stents.


Therefore, it would be desirable for the endoprosthesis to provide an elevated degree of scaffolding to a vessel wall while retaining an elevated degree of flexibility within the operating environments of the SFA and PA.


SUMMARY OF THE INVENTION

The present invention relates to an endoprosthesis for delivery within a body lumen that provides an elevated degree of scaffolding and that has an elevated degree of flexibility, making it particularly suited for implantation in body vessels in which extensive bending, compression, elongation, and torsion forces are applied to the endoprosthesis. In different embodiments, the endoprosthesis may be configured as a stent, graft, valve, occlusive device, trocar or aneurysm treatment device for a variety of intralumenal applications, including vascular, coronary, biliary, esophageal, renal, urological and gastrointestinal, for example, for the treatment of SFA and PA diseases.


An endoprosthesis constructed according to the principles of the present invention includes a web structure that is expandable from a contracted configuration to an expanded configuration and that includes a plurality of longitudinally adjacent web rings. Each of the web rings is defined by web elements disposed circumferentially around a longitudinal axis, which are adjoined one to the other at junction bends. A first junction bend in a first web ring is coupled to a second junction bend in a second web ring by a connector that includes three or more struts (for example, five struts) of essentially equal length that extend circumferentially in essentially parallel directions. The struts of the connector are adjoined in sequence by coupling segments that, in one embodiment of the invention, are arcuate in shape.


The connector of the present invention may also include two struts of reduced length, one coupled to the first junction bend and the other one coupled to the second junction bend. To increase density of the endoprosthesis, the coupling segments of one connector may be nested among the coupling segments of another connector adjacent in a circumferential direction.


In different embodiments, the connector may couple a midpoint in the first junction bend to a midpoint in the second junction bend, or may couple an endpoint in the first junction bend to an endpoint in the second junction bend. The first junction bend may be laterally offset in relation to the second junction bend, providing the endoprosthesis with greater ability to absorb torsional stresses.


The connector may span circumferentially for a distance substantially equal to the circumferential spacing between the midpoints of four junction bends, and the interstices between the struts may be narrower than the widths of the struts.


In different embodiments, the endoprosthesis may be a stent, and the struts of the connector may be substantially rectilinear in shape. The web elements may also be substantially rectilinear in shape, or may be shaped like crowns that include a central member disposed essentially parallel to the longitudinal axis of the endoprosthesis in the contracted configuration and connected at its ends to end members that extend at obtuse angles from the central member. In the contracted delivery configuration of the endoprosthesis, the web elements of each web ring are nested one into the other and may be oriented at approximately 180 degrees in relation to the web elements in a neighboring web ring.


The web structure may be manufactured from a shape-memory material and may be configured to self-expand from the contracted configuration to the expanded configuration, or may be expanded by application of a radial pressure to an interior surface of the essentially tubular body, for example, by inflating a balloon disposed inside the endoprosthesis.





BRIEF DESCRIPTION OF THE DRAWINGS

The drawings constitute a part of this specification and include exemplary embodiments of the invention, which may be embodied in various forms. It is to be understood that in some instances various aspects of the invention may be shown exaggerated or enlarged to facilitate an understanding of the invention.



FIG. 1 is a top view of the web structure of a first endoprosthesis, illustrated in a flattened state, according to an embodiment of the invention.



FIG. 2 is a detail view of the web structure of FIG. 1.



FIG. 3 illustrates an endoprosthesis according to an embodiment of the invention in an at rest state.



FIG. 4 illustrates the endoprosthesis of FIG. 3 in a bent state.



FIG. 5 illustrates the endoprosthesis of FIG. 3 in an elongated state.



FIG. 6 illustrates the endoprosthesis of FIG. 3 in a twisted state.





DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

Detailed descriptions of embodiments of the invention are provided herein. It is to be understood, however, that the present invention may be embodied in various forms. Therefore, the specific details disclosed herein are not to be interpreted as limiting, but rather as a representative basis for teaching one skilled in the art how to use the present invention in virtually any detailed system, structure or manner.


The present invention relates to an endoprosthesis for delivery within a body lumen that provides an elevated degree of scaffolding and that has an elevated degree of flexibility, making it particularly suited for implantation in body vessels in which extensive bending, compression, elongation, and torsion forces are applied to the endoprosthesis. In different embodiments, the endoprosthesis may be configured as a stent, graft, valve, occlusive device, trocar or aneurysm treatment device for a variety of intralumenal applications, including vascular, coronary, biliary, esophageal, renal, urological and gastrointestinal, for example, for the treatment of SFA and PA diseases.


An endoprosthesis constructed according to the principles of the present invention includes a web structure that is expandable from a contracted delivery configuration to an expanded deployed configuration and that is formed by a plurality of longitudinally adjacent web rings, coupled by connectors that include three or more struts of essentially equal length. The connector struts are joined in sequence and extend circumferentially in essentially parallel directions. For ease of description and without restrictive intent, an embodiment of the invention will be described hereinafter with reference to a stent.


Referring first to FIG. 1, a first embodiment of the invention relates to a stent 10, which is formed by a plurality of web rings 12 that are disposed longitudinally one next to the other and that are adjoined by connectors 14 constructed as described in greater detail hereinbelow. Although the structure of stent 10 is shown in FIG. 1 in flattened form, a person skilled in the art will appreciate that stent 10 is manufactured for clinical use as an essentially tubular body that may have a variety of shapes, for example, a cylindrical, frustoconical, or hyperboloid shape.


Stent 10 may be produced from a variety of biocompatible materials and may be deployed at a target vessel using techniques also known in the art. For example, stent 10 may be manufactured from a shape memory material such as Nitinol (a nickel-titanium alloy) when stent 10 is structured to self-expand after delivery into the target vessel, or may be manufactured from a plastic or metal material such as stainless steel or cobalt chromium alloys when stent 10 is structured to be expanded by inflating a catheter-mounted balloon on which stent 10 is crimped.


Referring now to FIG. 2, connector 14 includes a plurality of struts 16 that extend circumferentially along the surface of stent 10 in essentially parallel directions. In the illustrated embodiment, five struts 16 of equal length are disposed in circumferential directions and are adjoined sequentially by coupling segments 18, but a higher or lower number of struts 16 (e.g. 2, 3, 4, 6, or 7) and coupling segments 18 (e.g. 3, 4, 5, 7, or 8) may be employed, depending on the distances between the web rings and on the desired density (i.e., on the desired amount of material per surface units) of connector 16.


Coupling segments 18 are shown in FIG. 2 as being arcuate, which is a preferred embodiment of the invention because of the optimal stress distribution of stress in rounded segments in comparison with other segment designs. It should be understood, however, that coupling segments 18 may have a variety of other shapes and that shapes that do not contain points of stress concentration are preferred because the risk of stent rupture is reduced with this type of design.


Connector 14 also includes two struts 20 and 22 of reduced length, which are disposed at opposite ends of connector 14 and which couple connector 14 to neighboring web rings 26 and 30. More particularly, strut 20 joins connector 14 to a first junction bend 24 in first web ring 26 and strut 22 joins connector 14 to a second junction bend 28 in second web ring 30.


First junction bend 24 and second junction bend 28 are shown in FIG. 2 as laterally offset one from the other, that is, not aligned longitudinally. This offset arrangement is preferable over arrangements in which first and second junction bends are longitudinally aligned, because this offset arrangement provides for an improved resistance to foreshortening during stent deployment and as a consequence of bending, compression, elongation and torsion stresses applied to stent 10 after implantation.


While FIG. 2 shows that struts 20 and 22 are coupled to the mid-points of junction bends 24 and 28, in other embodiments of the invention struts 20 and 22 may be coupled to other points of junction bends 24 and 28, for example, struts 20 and 22 may be coupled to (or near) the end points of junction bends 24 and 28, in order to maximize the offset distance between junction bends 24 and 28.


In different embodiments, struts 16 may have different lengths. For example, in the embodiment illustrated in FIG. 2, struts 16 are shown as having the same length as the distance between four junction bends in web ring 26 or 30. In other embodiments of the invention, struts 16 may have a variety of other lengths. Further, FIG. 2 shows struts 16 as essentially rectilinear in shape, but in other embodiments of the invention struts 16 may be each formed by a plurality of segments coupled at different angles (in a fashion similar to the web elements defining web rings 26 and 30) or may even have a curved shape.


In different embodiments, struts 16 may also have a variety of different widths. For example, in the embodiment illustrated in FIG. 2, struts 16 are shown as having widths larger than interstices 32 between struts 16, which provides stent 10 with a high degree of surface density and, accordingly, with elevated scaffolding properties.


A plurality of connectors are aligned circumferentially to couple first web ring 26 to second web ring 30 and the distances between two circumferentially adjacent connectors may vary in different embodiments of the invention. In the embodiment illustrated in FIG. 2, connector 14 is disposed as closely as possible to circumferentially adjacent connector 34, such that coupling segments 36 of connector 34 are nested among coupling segments 18 of connector 14.


The web elements of stent 10 may be shaped as crowns 38 adjoined sequentially by junction bends, as illustrated in FIG. 2. More particularly, each of the web elements or crowns 38 depicted in FIG. 2 is formed by a central member 40, disposed essentially parallel to the longitudinal axis of stent 10 in the contracted configuration of stent 10, and by a first and a second end members 42 and 44 that extend from opposite ends of central member 40 at two obtuse angles, which may be the same or different.


In the contracted delivery configuration, crown 38 are nested one into the other. Further, the crowns of neighboring web rings may be disposed in opposite directions, for example, as shown in FIG. 2, the crowns of first web ring 36 may be disposed at 180 degrees in relation to the crowns of second web ring 30. Stents having web elements shaped like the crowns shown in FIG. 2 are described in U.S. Patent Application Publication Nos. 2004/0193250, 2005/0004651, U.S. Pat. Nos. 6,682,554 and 6,602,285, International Publication No. WO 00/13611, and German Patent Publication No. 19840645, the entireties of which are incorporated herein by reference.


A person skilled in the art will appreciate that web elements of still different shapes may be employed in constructing the web rings and that such alternative designs all fall within the spirit and scope of the present invention. For example, the web elements of web rings 26 and 30 may be shaped like essentially rectilinear struts joined one to the other by arcuate junction bends.


The architecture of stent 10 is particularly stable, as can be seen from the photographs enclosed herein as FIGS. 3-6. Referring first to FIG. 3, stent 10 is shown in an at-rest position, without any loads applied thereon. Therefore, FIG. 3 depicts illustrates stent 10 in the configuration described in detail hereinabove, except that FIGS. 1-2 depict stent 10 in a flattened configuration while FIG. 3 reproduces stent 10 in a cylindrical, operative configuration.



FIG. 4 depicts stent 10 in a bent configuration. It can be seen that stent 10 still retains its tubular configuration after bending because of the stretching of the connectors (either longitudinally or in fan-like fashion) in the areas of stent 10 under tension, and of the compressing of the connectors (also either longitudinally or in fan-like fashion) in the areas of stent 10 under compression.



FIG. 5 depicts stent 10 in an elongated mode, as a result of tensile forces applied to the longitudinal ends of stent 10. The stable architecture of stent 10 can be seen again, because stent 10 continues to maintain its tubular structure under the applied load.



FIG. 6 depicts stent 10 when a torsion force applied to its longitudinal ends. As it can be seen, the construction of stent 10 with connectors configured as described hereinabove and coupled to junction bends that are laterally offset from each other causes the connectors to absorb part or all of the torsional stress transmitted between neighboring web rings, which would otherwise cause the neighboring web rings to rotate one in relation to the other and stent 10 to become deformed, possibly leading to the ultimate fracture of stent 10.


Therefore, an endoprosthesis constructed according to the principles of the present invention will have a stable architecture, preventing traumas to the vessel and to the stent and reducing fractures of the endoprosthesis during service.


While the invention has been described in connection with the above described embodiments, it is not intended to limit the scope of the invention to the particular forms set forth, but on the contrary, it is intended to cover such alternatives, modifications, and equivalents as may be included within the scope of the invention. Further, the scope of the present invention fully encompasses other embodiments that may become obvious to those skilled in the art and the scope of the present invention is limited only by the appended claims.

Claims
  • 1. An endoprosthesis for delivery in a body lumen comprising: a tubular body having a longitudinal axis, and having proximal and distal ends and a lumen extending longitudinally therebetween, and a wall having areas thereof removed to define a web structure configured for circumferential expansion from a contracted delivery configuration to an expanded deployed configuration;the web structure comprising a plurality of longitudinally adjacent web rings interconnected one with another at a plurality of connectors, and that are arranged so that the plurality of web rings are situated side-by-side along the longitudinal length of the tubular body, with each web ring extending circumferentially around the wall, and each web ring comprising web elements joined in pairs at junction bends, each web ring joined in pairs by the plurality of connectors at at least some of the junction bends, the web elements in each web ring are foldable on top of one another and nested one into the other in the contracted delivery configuration, each of the web elements comprising a central member having first and second ends, the central member being disposed parallel to the longitudinal axis in the contracted delivery configuration, the central member being connected at the first end to a first end member at a first obtuse angle, the central member being connected at the second end to a second end member at a second obtuse angle, wherein adjacent web rings comprise a proximal web ring and a distal web ring, the web elements in the proximal web ring being oriented at 180 degrees in relation to the web elements in the distal web ring;wherein each connector is coupled to a mid-point of its respective junction bends, and each connector is disposed between opposing junction bends of a pair of web rings situated side-by-side, with the opposing junction bends of each web ring facing one another, such that each connector is disposed between the pair of web rings and is longitudinally offset from the pair of web rings, and each connector comprising a plurality of parallel struts joined at arcuate coupling segments so that the parallel struts can be expanded and contracted relative to one another when the stent is stretched or compressed when deployed, the plurality of parallel struts extending circumferentially around at least a portion of the wall a distance that is equal to the spacing between four circumferentially adjacent junction bends on each side of the connector, and each connector being joined on one side to a first pair of web elements of a first web ring at a first junction bend, and joined on its opposite side to a second pair of web elements of an adjacent web ring at a second junction bend, the second pair of web elements being laterally offset from the first pair of web elements;wherein arcuate coupling segments of a first connector are nested between arcuate coupling segments of a second circumferentially adjacent connector.
  • 2. The endoprosthesis of claim 1, the connector comprising at least five struts of equal length.
  • 3. The endoprosthesis of claim 1, the connector further comprising two struts of reduced length, and one of the struts of reduced length being coupled to the first junction bend and the other strut of reduced length being coupled to the second junction bend.
  • 4. The endoprosthesis of claim 1, the plurality of parallel struts comprising one or more pairs of adjacent parallel struts, the plurality of parallel struts defining interstices between each pair of adjacent parallel struts, the interstices having a longitudinal width that is smaller than a combined longitudinal width of one of the pairs of adjacent parallel struts.
  • 5. The endoprosthesis of claim 1, the connector coupling an endpoint in the first junction bend to an endpoint in the second junction bend.
  • 6. The endoprosthesis of claim 1, the endoprosthesis being a stent.
  • 7. The endoprosthesis of claim 1, the struts being rectilinear in shape.
  • 8. The endoprosthesis of claim 1, the web elements being rectilinear in shape.
  • 9. The endoprosthesis of claim 1, the web structure being configured to self-expand from the contracted delivery configuration to the expanded deployed configuration.
  • 10. The endoprosthesis of claim 1, the web structure being configured to expand from the contracted delivery configuration to the expanded deployed configuration by application of a radial pressure to an interior surface of the tubular body.
  • 11. The endoprosthesis of claim 1, the first and the second obtuse angles being equal.
  • 12. The endoprosthesis of claim 1, the junction bends having an arcuate shape.
  • 13. An endoprosthesis for delivery in a body lumen comprising: a tubular body having a longitudinal axis, and having proximal and distal ends and a lumen extending longitudinally therebetween, and a wall having areas thereof removed to define a web structure configured for circumferential expansion from a contracted delivery configuration to an expanded deployed configuration;the web structure comprising a plurality of longitudinally adjacent web rings interconnected one with another at a plurality of serpentine connectors, and that are arranged so that the plurality of web rings are situated side-by-side along the longitudinal length of the tubular body, with each web ring extending circumferentially around the wall, and each web ring comprising web elements joined in pairs at junction bends, each web ring joined in pairs by the plurality of serpentine connectors at at least some of the junction bends, the web elements in each web ring are foldable on top of one another and nested into the other in the contracted delivery configuration, each of the web elements comprising a central member having first and second ends, the central member being disposed parallel to the longitudinal axis in the contracted delivery configuration, the central member being connected at the first end to a first end member at a first obtuse angle, the central member being connected at the second end to a second end member at a second obtuse angle, wherein adjacent web rings comprise a proximal web ring and a distal web ring, the web elements in the proximal web ring being oriented at 180 degrees in relation to the web elements in the distal web ring;wherein each serpentine connector is coupled to a mid-point of its respective junction bends, and each connector is disposed between opposing junction bends of a pair of web rings situated side-by-side, with the opposing junction bends of each web ring facing one another, such that each serpentine connector is disposed between the pair of web rings and is longitudinally offset from the pair of web rings, and each serpentine connector comprising a plurality of parallel struts joined at arcuate coupling segments so that the parallel struts can be expanded and contracted relative to one another when the stent is stretched or compressed when deployed, the plurality of parallel struts extending circumferentially around at least a portion of the wall a distance that is equal to the spacing between four circumferentially adjacent junction bends on each side of the serpentine connector, and each serpentine connector being joined on one side to a first pair of web elements of a first web ring at a first junction bend, and joined on its opposite side to a second pair of web elements of an adjacent web ring at a second junction bend, and the second pair of web elements being laterally offset from the first pair of web elements,wherein arcuate coupling segments of a first serpentine connector are nested between arcuate coupling segments of a second circumferentially adjacent serpentine connector.
US Referenced Citations (288)
Number Name Date Kind
4475972 Wong Oct 1984 A
4580568 Gianturco Apr 1986 A
4738740 Pinchuk et al. Apr 1988 A
4743252 Martin, Jr. et al. May 1988 A
4759757 Pinchuk Jul 1988 A
4776337 Palmaz Oct 1988 A
4800882 Gianturco Jan 1989 A
4907336 Gianturco Mar 1990 A
5015253 MacGregor May 1991 A
5019090 Pinchuk May 1991 A
5041126 Gianturco Aug 1991 A
5059211 Stack et al. Oct 1991 A
5102417 Palmaz Apr 1992 A
5104404 Wolff Apr 1992 A
5116360 Pinchuk et al. May 1992 A
5122154 Rhodes Jun 1992 A
5133732 Wiktor Jul 1992 A
5147370 McNamara et al. Sep 1992 A
5163951 Pinchuk et al. Nov 1992 A
5171262 MacGregor Dec 1992 A
5221261 Termin et al. Jun 1993 A
5282823 Schwartz et al. Feb 1994 A
5292331 Boneau Mar 1994 A
5314444 Gianturco May 1994 A
5370683 Fontaine Dec 1994 A
5378239 Termin et al. Jan 1995 A
5380299 Fearnot et al. Jan 1995 A
5421955 Lau et al. Jun 1995 A
5443458 Eury Aug 1995 A
5443496 Schwartz et al. Aug 1995 A
5449373 Pinchasik et al. Sep 1995 A
5449382 Dayton Sep 1995 A
5476508 Amstrup Dec 1995 A
5496277 Termin et al. Mar 1996 A
5514154 Lau et al. May 1996 A
5527354 Fontaine et al. Jun 1996 A
5556414 Turi Sep 1996 A
5569295 Lam Oct 1996 A
5591197 Orth et al. Jan 1997 A
5591224 Schwartz et al. Jan 1997 A
5593417 Rhodes Jan 1997 A
5593442 Klein Jan 1997 A
5603721 Lau et al. Feb 1997 A
5609606 O'Boyle Mar 1997 A
5628788 Pinchuk May 1997 A
5630829 Lauterjung May 1997 A
5632772 Alcime et al. May 1997 A
5639278 Dereume et al. Jun 1997 A
5649952 Lam Jul 1997 A
5651174 Schwartz et al. Jul 1997 A
5653747 Dereume Aug 1997 A
5670161 Healy et al. Sep 1997 A
5674242 Phan et al. Oct 1997 A
5674277 Freitag Oct 1997 A
5693085 Buirge et al. Dec 1997 A
5695516 Fischell et al. Dec 1997 A
5697971 Fischell et al. Dec 1997 A
5700285 Myers et al. Dec 1997 A
5707386 Schnepp-Pesch et al. Jan 1998 A
5707388 Lauterjung Jan 1998 A
5709703 Lukic et al. Jan 1998 A
5709713 Evans et al. Jan 1998 A
5716393 Lindenberg et al. Feb 1998 A
5723003 Winston et al. Mar 1998 A
5723004 Dereume et al. Mar 1998 A
5728158 Lau et al. Mar 1998 A
5733303 Israel et al. Mar 1998 A
5735892 Myers et al. Apr 1998 A
5735893 Lau et al. Apr 1998 A
5735897 Buirge Apr 1998 A
5738817 Danforth et al. Apr 1998 A
5741325 Chaikof et al. Apr 1998 A
5741327 Frantzen Apr 1998 A
5743874 Fischell et al. Apr 1998 A
5749880 Banas et al. May 1998 A
5755771 Penn et al. May 1998 A
5755772 Evans et al. May 1998 A
5755774 Pinchuk May 1998 A
5755781 Jayaraman May 1998 A
5769884 Solovay Jun 1998 A
5776161 Globerman Jul 1998 A
5776181 Lee et al. Jul 1998 A
5776183 Kanesaka et al. Jul 1998 A
5782904 White et al. Jul 1998 A
5800526 Anderson et al. Sep 1998 A
5807404 Richter Sep 1998 A
5810868 Lashinski et al. Sep 1998 A
5810870 Myers et al. Sep 1998 A
5810872 Kanesaka et al. Sep 1998 A
5814063 Freitag Sep 1998 A
5817126 Imran Oct 1998 A
5824037 Fogarty et al. Oct 1998 A
5824045 Alt Oct 1998 A
5824048 Tuch Oct 1998 A
5824054 Khosravi et al. Oct 1998 A
5824059 Wijay Oct 1998 A
5827321 Roubin et al. Oct 1998 A
5836964 Richter et al. Nov 1998 A
5836966 St. Germain Nov 1998 A
5843120 Israel et al. Dec 1998 A
5843158 Lenker et al. Dec 1998 A
5843161 Solovay Dec 1998 A
5843164 Frantzen et al. Dec 1998 A
5846247 Unsworth et al. Dec 1998 A
5853419 Imran Dec 1998 A
5855598 Pinchuk Jan 1999 A
5855600 Alt Jan 1999 A
5860999 Schnepp-Pesch et al. Jan 1999 A
5861027 Trapp Jan 1999 A
5868781 Killion Feb 1999 A
5871538 Dereume Feb 1999 A
5876449 Starck et al. Mar 1999 A
5876450 Johlin, Jr. Mar 1999 A
5895406 Gray et al. Apr 1999 A
5897589 Cottenceau et al. Apr 1999 A
5922021 Jang Jul 1999 A
5928248 Acker Jul 1999 A
5938682 Hojeibane et al. Aug 1999 A
5948018 Dereume et al. Sep 1999 A
5954743 Jang Sep 1999 A
5968091 Pinchuk et al. Oct 1999 A
5968561 Batchelder et al. Oct 1999 A
5980552 Pinchasik et al. Nov 1999 A
5984965 Knapp et al. Nov 1999 A
6019789 Dinh et al. Feb 2000 A
6027526 Limon et al. Feb 2000 A
6033433 Ehr et al. Mar 2000 A
6033434 Borghi Mar 2000 A
6033435 Penn et al. Mar 2000 A
6039756 Jang Mar 2000 A
6048361 Von Oepen Apr 2000 A
6056767 Boussignac et al. May 2000 A
6059811 Pinchasik et al. May 2000 A
6068656 Von Oepen May 2000 A
6071308 Ballou et al. Jun 2000 A
6086610 Duerig et al. Jul 2000 A
6099561 Alt Aug 2000 A
6106548 Roubin et al. Aug 2000 A
6113627 Jang Sep 2000 A
6117165 Becker Sep 2000 A
6117535 Szycher et al. Sep 2000 A
6132460 Thompson Oct 2000 A
6136023 Boyle Oct 2000 A
6152957 Jang Nov 2000 A
6165212 Dereume et al. Dec 2000 A
6168409 Fare Jan 2001 B1
6174326 Kitaoka et al. Jan 2001 B1
6179868 Burpee et al. Jan 2001 B1
6190403 Fischell et al. Feb 2001 B1
6193744 Ehr et al. Feb 2001 B1
6193747 Von Oepen Feb 2001 B1
6200334 Jang Mar 2001 B1
6200335 Igaki Mar 2001 B1
6203569 Wijay Mar 2001 B1
6231598 Berry et al. May 2001 B1
6231600 Zhong May 2001 B1
6241762 Shanley Jun 2001 B1
6245101 Drasler et al. Jun 2001 B1
6253443 Johnson Jul 2001 B1
6258116 Hojeibane Jul 2001 B1
6261318 Lee et al. Jul 2001 B1
6264688 Herklotz et al. Jul 2001 B1
6264690 Von Oepen Jul 2001 B1
6270524 Kim Aug 2001 B1
6273913 Wright et al. Aug 2001 B1
6299604 Ragheb et al. Oct 2001 B1
6299635 Frantzen Oct 2001 B1
6325825 Kula et al. Dec 2001 B1
6331189 Wolinsky et al. Dec 2001 B1
6332089 Acker et al. Dec 2001 B1
6340366 Wijay Jan 2002 B2
6348065 Brown et al. Feb 2002 B1
6377835 Schoenberg et al. Apr 2002 B1
6395020 Ley et al. May 2002 B1
6416539 Hassdenteufel Jul 2002 B1
6436132 Patel et al. Aug 2002 B1
6443982 Israel et al. Sep 2002 B1
6451049 Vallana et al. Sep 2002 B2
6485508 McGuinness Nov 2002 B1
6488702 Besselink Dec 2002 B1
6491718 Ahmad Dec 2002 B1
6503272 Duerig et al. Jan 2003 B2
6506211 Skubitz et al. Jan 2003 B1
6508834 Pinchasik et al. Jan 2003 B1
6540776 Sanders Millare et al. Apr 2003 B2
6558415 Thompson May 2003 B2
6562065 Shanley May 2003 B1
6572646 Boylan et al. Jun 2003 B1
6589276 Pinchasik et al. Jul 2003 B2
6602285 Von Oepen et al. Aug 2003 B1
6616689 Ainsworth et al. Sep 2003 B1
6624097 Martin et al. Sep 2003 B2
D481139 Seibold et al. Oct 2003 S
6629994 Gomez et al. Oct 2003 B2
6652574 Jayaraman Nov 2003 B1
6676701 Rourke et al. Jan 2004 B2
6679911 Burgermeister Jan 2004 B2
6682554 Oepen et al. Jan 2004 B2
6723119 Pinchasik et al. Apr 2004 B2
6730252 Teoh et al. May 2004 B1
6740114 Burgermeister May 2004 B2
6749629 Hong et al. Jun 2004 B1
6755856 Fierens et al. Jun 2004 B2
6761733 Chobotov et al. Jul 2004 B2
6770088 Jang Aug 2004 B1
6776794 Hong et al. Aug 2004 B1
6786922 Schaeffer Sep 2004 B2
6790227 Burgermeister Sep 2004 B2
6796999 Pinchasik Sep 2004 B2
6821292 Pazienza et al. Nov 2004 B2
6846323 Yip et al. Jan 2005 B2
6875228 Pinchasik et al. Apr 2005 B2
6881222 White et al. Apr 2005 B2
6896697 Yip et al. May 2005 B1
6913619 Brown et al. Jul 2005 B2
6942689 Majercak Sep 2005 B2
6955686 Majercak et al. Oct 2005 B2
6998060 Tomonto Feb 2006 B2
7029493 Majercak et al. Apr 2006 B2
7060093 Dang et al. Jun 2006 B2
7128756 Lowe et al. Oct 2006 B2
7141062 Pinchasik et al. Nov 2006 B1
7179286 Lenz Feb 2007 B2
7204848 Brown et al. Apr 2007 B1
7329277 Addonizio et al. Feb 2008 B2
7520892 Ainsworth et al. Apr 2009 B1
7611531 Calisse Nov 2009 B2
7625398 Clifford et al. Dec 2009 B2
7686843 Moore Mar 2010 B2
7766956 Jang Aug 2010 B2
20010007955 Drasler et al. Jul 2001 A1
20010027339 Boatman et al. Oct 2001 A1
20010049549 Boylan et al. Dec 2001 A1
20020019660 Gianotti et al. Feb 2002 A1
20020055770 Doran et al. May 2002 A1
20020065549 White et al. May 2002 A1
20020107560 Richter Aug 2002 A1
20020111669 Pazienza et al. Aug 2002 A1
20020113331 Zhang et al. Aug 2002 A1
20020151964 Smith et al. Oct 2002 A1
20020169499 Zilla et al. Nov 2002 A1
20030055487 Calisse Mar 2003 A1
20030083736 Brown et al. May 2003 A1
20030114918 Garrison et al. Jun 2003 A1
20030120334 Gerberding Jun 2003 A1
20040002753 Burgermeister et al. Jan 2004 A1
20040051201 Greenhalgh et al. Mar 2004 A1
20040093073 Lowe et al. May 2004 A1
20040102836 Fischell et al. May 2004 A1
20040126405 Sahatjian et al. Jul 2004 A1
20040167615 Lenz Aug 2004 A1
20040193250 Von Oepen et al. Sep 2004 A1
20040230293 Yip et al. Nov 2004 A1
20040236407 Fierens et al. Nov 2004 A1
20040243220 Gianotti et al. Dec 2004 A1
20040267353 Gregorich Dec 2004 A1
20050004650 Oepen et al. Jan 2005 A1
20050004651 Von Oepen et al. Jan 2005 A1
20050004658 Oepen et al. Jan 2005 A1
20050004659 Von Oepen et al. Jan 2005 A1
20050004662 Von Oepen et al. Jan 2005 A1
20050043777 Von Oepen et al. Feb 2005 A1
20050043778 Von Oepen et al. Feb 2005 A1
20050075716 Yan Apr 2005 A1
20050222671 Schaeffer et al. Oct 2005 A1
20060015173 Clifford et al. Jan 2006 A1
20060106452 Niermann May 2006 A1
20060142844 Lowe et al. Jun 2006 A1
20060175727 Fierens et al. Aug 2006 A1
20060184232 Gianotti et al. Aug 2006 A1
20060206195 Calisse Sep 2006 A1
20060247759 Burpee et al. Nov 2006 A1
20070021827 Lowe et al. Jan 2007 A1
20070021834 Young et al. Jan 2007 A1
20070135891 Schneider Jun 2007 A1
20070179593 Fierens et al. Aug 2007 A1
20070179601 Fierens et al. Aug 2007 A1
20070213800 Fierens et al. Sep 2007 A1
20070299505 Gregorich et al. Dec 2007 A1
20080077231 Heringes et al. Mar 2008 A1
20080294239 Casey Nov 2008 A1
20080294240 Casey Nov 2008 A1
20090163992 Osman et al. Jun 2009 A1
20090163997 Casey Jun 2009 A1
20090163998 Casey Jun 2009 A1
20100057190 Issenmann Mar 2010 A1
20110004289 Oepen et al. Jan 2011 A1
20120165921 Casey Jun 2012 A1
Foreign Referenced Citations (62)
Number Date Country
2309079 Nov 2004 CA
19840645 Sep 1998 DE
0357003 Mar 1990 EP
0221570 Jan 1991 EP
565251 Oct 1993 EP
0699451 Mar 1996 EP
0709067 May 1996 EP
0808614 Nov 1997 EP
0815806 Jan 1998 EP
0928605 Jul 1999 EP
0950386 Oct 1999 EP
0983753 Mar 2000 EP
1042997 Oct 2000 EP
1095631 May 2001 EP
1516600 Mar 2005 EP
2774279 Aug 1999 FR
2344053 May 2000 GB
7-24072 Jan 1995 JP
08-206226 Aug 1996 JP
09-010318 Jan 1997 JP
10-328216 Dec 1998 JP
11-299901 Feb 1999 JP
2000312721 Nov 2000 JP
WO9117789 Nov 1991 WO
WO9621404 Jul 1996 WO
WO9625124 Aug 1996 WO
WO9626689 Sep 1996 WO
WO9712563 Apr 1997 WO
WO9712564 Apr 1997 WO
WO9714375 Apr 1997 WO
WO9832412 Jul 1998 WO
WO9847447 Oct 1998 WO
WO9907308 Feb 1999 WO
WO9917680 Apr 1999 WO
WO9923976 May 1999 WO
WO9938456 Aug 1999 WO
WO9938458 Aug 1999 WO
WO9939660 Aug 1999 WO
WO9939663 Aug 1999 WO
WO9949928 Oct 1999 WO
WO 0013611 Mar 2000 WO
WO0018328 Apr 2000 WO
WO0032241 Jun 2000 WO
WO0045744 Aug 2000 WO
WO0053119 Sep 2000 WO
WO0101885 Jan 2001 WO
WO0182835 Nov 2001 WO
WO0226164 Apr 2002 WO
WO02064061 Aug 2002 WO
WO02064065 Aug 2002 WO
WO02094127 Nov 2002 WO
WO03009779 Feb 2003 WO
WO03057076 Jul 2003 WO
WO2004087015 Oct 2004 WO
WO2006055533 May 2006 WO
WO2006066886 Jun 2006 WO
WO2006099449 Sep 2006 WO
WO2008042618 Apr 2008 WO
WO2008142566 Nov 2008 WO
WO2009046973 Apr 2009 WO
WO2009080326 Jul 2009 WO
WO2009080327 Jul 2009 WO
Non-Patent Literature Citations (184)
Entry
U.S. Appl. No. 10/859,636, filed Mar. 30, 2011, Issue Notification.
U.S. Appl. No. 11/731,820, filed Mar. 30, 2011, Issue Notification.
U.S. Appl. No. 12/949,481, filed Nov. 18, 2010, Schneider.
U.S. Appl. No. 12/608,335, filed Oct. 29, 2009, Calisse.
U.S. Appl. No. 10/241,523, Aug. 18, 2004, Office Action.
U.S. Appl. No. 10/241,523, Oct. 25, 2004, Office Action.
U.S. Appl. No. 10/241,523, Mar. 8, 2005, Office Action.
U.S. Appl. No. 10/241,523, Jun. 3, 2005, Office Action.
U.S. Appl. No. 10/241,523, Aug. 23, 2005, Office Action.
U.S. Appl. No. 10/241,523, Nov. 16, 2005, Office Action.
U.S. Appl. No. 10/241,523, Apr. 27, 2006, Office Action.
U.S. Appl. No. 10/743,857, Feb. 12, 2010, Notice of Allowance.
U.S. Appl. No. 10/859,636, Feb. 1, 2010, Notice of Allowance.
U.S. Appl. No. 10/903,013, Feb. 12, 2010, Notice of Allowance.
U.S. Appl. No. 10/903,014, Feb. 5, 2010, Notice of Allowance.
U.S. Appl. No. 10/955,425, Feb. 26, 2010, Notice of Allowance.
U.S. Appl. No. 11/404,450, Apr. 22, 2010, Office Action.
U.S. Appl. No. 11/435,260, Jan. 10, 2008, Office Action.
U.S. Appl. No. 11/435,260, Mar. 26, 2008, Office Action.
U.S. Appl. No. 11/435,260, Dec. 16, 2008, Office Action.
U.S. Appl. No. 11/435,260, Jun. 18, 2009, Notice of Allowance.
U.S. Appl. No. 11/435,260, Jun. 26, 2009, Notice of Allowance.
U.S. Appl. No. 11/731,820, Jan. 27, 2010, Office Action.
U.S. Appl. No. 11/731,882, Feb. 3, 2010, Office Action.
U.S. Appl. No. 11/805,584, Apr. 27, 2009, Office Action.
U.S. Appl. No. 11/805,584, Oct. 29, 2009, Office Action.
U.S. Appl. No. 11/805,584, Mar. 15, 2010, Office Action.
U.S. Appl. No. 11/961,384, May 26, 2009, Office Action.
U.S. Appl. No. 11/961,384, Oct. 8, 2009, Office Action.
U.S. Appl. No. 11/961,754, Jul. 22, 2009, Office Action.
U.S. Appl. No. 11/961,754, Apr. 5, 2010, Notice of Allowance.
U.S. Appl. No. 11/973,707, Jun. 9, 2009, Office Action.
U.S. Appl. No. 11/973,707, Mar. 19, 2010, Office Action.
U.S. Appl. No. 11/961,775, Oct. 1, 2009, Office Action.
U.S. Appl. No. 11/961,775, Mar. 31, 2010, Office Action.
U.S. Appl. No. 12/608,335, May 11, 2012, Office Action.
U.S. Appl. No. 12/966,916, May 23, 2012, Notice of Allowance.
U.S. Appl. No. 60/637,495, filed Dec. 20, 2004, Fierens et al.
U.S. Appl. No. 09/582,318, Aug. 14, 2002, Office Action.
U.S. Appl. No. 09/582,318, Mar. 7, 2003, Notice of Allowance.
U.S. Appl. No. 09/742,144, Sep. 24, 2002, Office Action.
U.S. Appl. No. 09/742,144, May 14, 2003, Office Action.
U.S. Appl. No. 09/742,144, Aug. 29, 2003, Notice of Allowance.
U.S. Appl. No. 09/916,394, Aug. 12, 2003, Office Action.
U.S. Appl. No. 09/916,394, Oct. 9, 2003, Office Action.
U.S. Appl. No. 09/916,394, Mar. 2, 2004, Office Action.
U.S. Appl. No. 09/967,789, Sep. 17, 2003, Office Action.
U.S. Appl. No. 09/967,789, Feb. 17, 2004, Notice of Allowance.
U.S. Appl. No. 10/743,857, Mar. 15, 2007, Office Action.
U.S. Appl. No. 10/743,857, Nov. 16, 2007, Office Action.
U.S. Appl. No. 10/743,857, May 8, 2008, Office Action.
U.S. Appl. No. 10/743,857, Jan. 6, 2009, Office Action.
U.S. Appl. No. 10/743,857, May 27, 2009, Office Action.
U.S. Appl. No. 10/743,857, Jun. 25, 2010, Notice of Allowance.
U.S. Appl. No. 10/859,636, Jun. 1, 2007, Office Action.
U.S. Appl. No. 10/859,636, Dec. 31, 2007, Office Action.
U.S. Appl. No. 10/859,636, Apr. 15, 2008, Office Action.
U.S. Appl. No. 10/859,636, Oct. 1, 2008, Notice of Allowance.
U.S. Appl. No. 10/859,636, Mar. 5, 2009, Office Action.
U.S. Appl. No. 10/859,636, Oct. 19, 2009, Notice of Allowance.
U.S. Appl. No. 10/859,636, May 19, 2010, Notice of Allowance.
U.S. Appl. No. 10/884,613, Mar. 30, 2005, Office Action.
U.S. Appl. No. 10/884,613, Nov. 14, 2005, Office Action.
U.S. Appl. No. 10/903,013, Mar. 15, 2007, Office Action.
U.S. Appl. No. 10/903,013, Nov. 19, 2007, Office Action.
U.S. Appl. No. 10/903,013, May 14, 2008, Office Action.
U.S. Appl. No. 10/903,013, Jan. 5, 2009, Office Action.
U.S. Appl. No. 10/903,013, May 27, 2009, Office Action.
U.S. Appl. No. 10/903,013, Jun. 24, 2010, Notice of Allowance.
U.S. Appl. No. 10/903,014, Mar. 15, 2007, Office Action.
U.S. Appl. No. 10/903,014, Nov. 16, 2007, Office Action.
U.S. Appl. No. 10/903,014, May 13, 2008, Office Action.
U.S. Appl. No. 10/903,014, Jan. 13, 2009, Office Action.
U.S. Appl. No. 10/903,014, Jun. 1, 2009, Office Action.
U.S. Appl. No. 10/903,014, May 26, 2010, Office Action.
U.S. Appl. No. 10/903,014, Jun. 24, 2010, Notice of Allowance.
U.S. Appl. No. 10/903,080, Mar. 15, 2007, Office Action.
U.S. Appl. No. 10/903,080, Nov. 19, 2007, Office Action.
U.S. Appl. No. 10/903,080, May 12, 2008, Office Action.
U.S. Appl. No. 10/903,080, Dec. 30, 2008, Office Action.
U.S. Appl. No. 10/903,080, May 27, 2009, Office Action.
U.S. Appl. No. 10/903,080, Jan. 13, 2010, Notice of Allowance.
U.S. Appl. No. 10/909,117, Aug. 22, 2007, Office Action.
U.S. Appl. No. 10/909,117, May 12, 2008, Office Action.
U.S. Appl. No. 10/909,117, Dec. 30, 2008, Office Action.
U.S. Appl. No. 10/909,117, May 27, 2009, Office Action.
U.S. Appl. No. 10/909,117, Jan. 13, 2010, Notice of Allowance.
U.S. Appl. No. 10/909,118, Mar. 29, 2007, Office Action.
U.S. Appl. No. 10/909,118, Nov. 19, 2007, Office Action.
U.S. Appl. No. 10/909,118, May 12, 2008, Office Action.
U.S. Appl. No. 10/909,118, Jan. 5, 2009, Office Action.
U.S. Appl. No. 10/909,118, Jul. 24, 2009, Office Action.
U.S. Appl. No. 10/909,118, Jan. 13, 2010, Notice of Allowance.
U.S. Appl. No. 10/954,948, Mar. 15, 2007, Office Action.
U.S. Appl. No. 10/954,948, Nov. 16, 2007, Office Action.
U.S. Appl. No. 10/954,948, May 15, 2008, Office Action.
U.S. Appl. No. 10/954,948, Jan. 13, 2009, Office Action.
U.S. Appl. No. 10/954,948, May 29, 2009, Office Action.
U.S. Appl. No. 10/954,948, Jan. 13, 2010, Notice of Allowance.
U.S. Appl. No. 10/954,948, Jul. 6, 2010, Notice of Allowance.
U.S. Appl. No. 10/955,425, Mar. 15, 2007, Office Action.
U.S. Appl. No. 10/955,425, Nov. 16, 2007, Office Action.
U.S. Appl. No. 10/955,425, May 13, 2008, Office Action.
U.S. Appl. No. 10/955,425, Jan. 13, 2009, Office Action.
U.S. Appl. No. 10/955,425, May 28, 2009, Office Action.
U.S. Appl. No. 10/955,425, Jun. 25, 2010, Notice of Allowance.
U.S. Appl. No. 11/313,110, Jan. 8, 2008, Office Action.
U.S. Appl. No. 11/313,110, Jul. 2, 2008, Office Action.
U.S. Appl. No. 11/313,110, Mar. 3, 2009, Office Action.
U.S. Appl. No. 11/313,110, Nov. 2, 2009, Notice of Allowance.
U.S. Appl. No. 11/313,110, Feb. 18, 2010, Notice of Allowance.
U.S. Appl. No. 11/313,110, Jun. 15, 2010, Notice of Allowance.
U.S. Appl. No. 11/404,450, Feb. 4, 2009, Office Action.
U.S. Appl. No. 11/404,450, Mar. 17, 2009, Office Action.
U.S. Appl. No. 11/404,450, Sep. 30, 2009, Office Action.
U.S. Appl. No. 11/601,475, Jul. 22, 2008, Office Action.
U.S. Appl. No. 11/601,475, Jan. 6, 2009, Office Action.
U.S. Appl. No. 11/601,475, Jun. 1, 2009, Office Action.
U.S. Appl. No. 11/601,475, Jan. 15, 2010, Notice of Allowance.
U.S. Appl. No. 11/601,475, Jul. 9, 2010, Notice of Allowance.
U.S. Appl. No. 11/732,244, Sep. 28, 2009, Office Action.
U.S. Appl. No. 11/732,244, May 5, 2010, Notice of Allowance.
U.S. Appl. No. 11/732,244, Jun. 21, 2010, Notice of Allowance.
U.S. Appl. No. 11/973,707, Oct. 12, 2011, Notice of Allowance.
U.S. Appl. No. 10/909,118, Sep. 21, 2010, Notice of Allowance.
U.S. Appl. No. 11/805,584, Oct. 4, 2010, Office Action.
U.S. Appl. No. 12/895,032, filed Sep. 30, 2010, Fierens et al.
U.S. Appl. No. 10/903,080, Jan. 26, 2011, Issue Notification.
U.S. Appl. No. 11/601,475, Jan. 26, 2011, Issue Notification.
U.S. Appl. No. 12/966,916, Jun. 10, 2011, Office Action.
U.S. Appl. No. 12/895,032, Jul. 3, 2012, Office Action.
U.S. Appl. No. 11/973,707, Feb. 15, 2012, Issue Notification.
U.S. Appl. No. 12/949,481, Feb. 15, 2012, Office Action.
U.S. Appl. No. 11/731,882, Dec. 14, 2011, Issue Notification.
U.S. Appl. No. 12/949,481, Jan. 5, 2012, Office Action.
U.S. Appl. No. 12/966,916, Jan. 5, 2012, Office Action.
U.S. Appl. No. 11/404,450, Jan. 31, 2012, Office Action.
U.S. Appl. No. 12/895,032, Feb. 1, 2012, Office Action.
U.S. Appl. No. 11/805,584, May 12, 2011, Notice of Allowance.
U.S. Appl. No. 13/089,039, filed Apr. 8, 2011, Fierens et al.
U.S. Appl. No. 10/743,857, Aug. 18, 2010, Issue Notification.
U.S. Appl. No. 10/903,013, Aug. 18, 2010, Issue Notification.
U.S. Appl. No. 11/731,820, Aug. 5, 2010, Notice of Allowance.
U.S. Appl. No. 11/961,754, Jul. 28, 2010, Notice of Allowance.
U.S. Appl. No. 11/404,450, Nov. 26, 2010, Office Action.
U.S. Appl. No. 10/859,636, Dec. 9, 2010, Notice of Allowance.
U.S. Appl. No. 11/961,754, Nov. 23, 2010, Issue Notification.
U.S. Appl. No. 12/966,916, filed Dec. 13, 2010, Casey.
U.S. Appl. No. 10/909,117, Nov. 17, 2010, Issue Notification.
U.S. Appl. No. 11/731,820, Dec. 16, 2010, Notice of Allowance.
U.S. Appl. No. 11/404,450, Aug. 10, 2011, Office Action.
U.S. Appl. No. 11/961,384, Apr. 23, 2012, Office Action.
U.S. Appl. No. 12/875,971, Apr. 19, 2012, Office Action.
U.S. Appl. No. 11/731,882, Aug. 29, 2011, Notice of Allowance.
U.S. Appl. No. 11/805,584, Aug. 24, 2011, Issue Notification.
U.S. Appl. No. 10/903,014, Aug. 25, 2010, Issue Notification.
U.S. Appl. No. 10/903,080, Sep. 16, 2010, Notice of Allowance.
U.S. Appl. No. 10/909,117, Sep. 16, 2010, Notice of Allowance.
U.S. Appl. No. 10/955,425, Sep. 30, 2010, Notice of Allowance.
U.S. Appl. No. 11/313,110, Sep. 29, 2010, Issue Notification.
U.S. Appl. No. 11/731,882, Sep. 1, 2010, Office Action.
U.S. Appl. No. 11/732,244, Sep. 22, 2010, Issue Notification.
Landers, Rüdiger and Mülhaupt, Rolf “Desktop manufacturing of complex objects, prototypes and biomedical scaffolds by means of computer-assisted design combined with computer-guided 3D plotting of polymers and reactive oligomers” Macromolecular Materials and Engineering , vol. 282, Issue 1, pp. 17-21, Oct. 2000.
U.S. Appl. No. 11/961,384, Aug. 21, 2012, Notice of Allowance.
U.S. Appl. No. 12/875,971, Jul. 26, 2012, Notice of Allowance.
U.S. Appl. No. 12/875,971, Oct. 17, 2012, Issue Notification.
U.S. Appl. No. 12/949,481, Aug. 13, 2012, Notice of Allowance.
U.S. Appl. No. 13/089,039, Oct. 16, 2012, Office Action.
U.S. Appl. No. 13/411,135, Oct. 16, 2012, Restriction Requirement.
U.S. Appl. No. 12/895,032, Aug. 13, 2013, Office Action.
U.S. Appl. No. 13/089,039, Jun. 28, 2013, Office Action.
U.S. Appl. No. 13/411,135, Mar. 15, 2013, Office Action.
U.S. Appl. No. 13/801,469, filed Mar. 13, 2013, Von Oepen et al.
U.S. Appl. No. 12/608,335, Dec. 2, 2013, Office Action.
U.S. Appl. No. 12/608,335, Mar. 3, 2014, Advisory Action.
U.S. Appl. No. 12/895,032, Oct. 29, 2013, Office Action.
U.S. Appl. No. 12/895,032, Mar. 14, 2014, Office Action.
U.S. Appl. No. 13/089,039, Sep. 26, 2013, Office Action.
U.S. Appl. No. 13/089,039, Apr. 14, 2014, Notice of Allowance.
U.S. Appl. No. 13/089,039, Aug. 6, 2014, Issue Notification.
U.S. Appl. No. 13/411,135, Oct. 8, 2013, Office Action.
U.S. Appl. No. 13/411,135, Mar. 14, 2014, Office Action.
U.S. Appl. No. 14/323,658, filed Jul. 3, 2014, Fierens et al.
U.S. Appl. No. 13/411,135, Oct. 24, 2014, Office Action.
Related Publications (1)
Number Date Country
20090163996 A1 Jun 2009 US